



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspio.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/764,818	01/26/2004	Patricia A. Brown	AVSI-0033 (108328.00170)		
7590 08/24/2005			EXAMINER		
T. Ling Chwang			SCHNIZER, RICHARD A		
Jackson Walker	L.L.P.			<u> </u>	
#600			ART UNIT	PAPER NUMBER	
2435 North Central Expressway			1635		
Richardson, TX 75080			DATE MAILED: 08/24/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/764,818	BROWN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Richard Schnizer, Ph. D	1635				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠ Responsive to communication(s) filed on <u>31 May 2005</u> .						
	•					
3) Since this application is in condition for allowan	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-9,11-20,22-28,30-77,79,80,86,88,89,97 and 99</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.	Claim(s) is/are rejected.					
7)☐ Claim(s) is/are objected to.	Claim(s) is/are objected to.					
8) Claim(s) 1-9, 11-20, 22-28, 30-77, 79, 80, 86, 88, 89, 97, and 99 are subject to restriction and/or election						
requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)						
Notice of Draftsperson's Patent Drawing Review (PTO-948)     Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)     Paper No(s)/Mail Date	Paper No(s)/Mail Dai 5) Notice of Informal Pa 6) Other:	e				

## **DETAILED ACTION**

The Examiner and art unit responsible for this application have changed. Please forward further correspondence to Richard Schnizer whose contact information is given at the end of this Action.

An amendment was received and entered on 5/31/05.

Claims 10, 21, 29, 78, 81-85, 87, 90-96, and 98 were canceled as requested.

Claims 1-9, 11-20, 22-28, 30-77, 79, 80, 86, 88, 89, 97, and 99 remain pending and are under consideration in this Office Action.

The previous Action mailed 2/9/05, including the indicated allowability of claims 58-76, is withdrawn in favor of the following restriction requirement.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Groups 1, claims 1-9, 11-20, 22-28, 30-76, drawn to methods of decreasing involuntary cull in farm animals, improving body condition score (BCS) in farm animals, or increasing milk production in dairy cows by delivering into muscle of the animal, or into tissue of the cow, an expression construct encoding a growth hormone releasing hormone (GHRH), classified in class 514, subclass 44.
- Group 2, claims 77, 79, 80, 86, 88, 89, 97, and 99, drawn to methods of decreasing involuntary cull in farm animals, improving body condition score (BCS) in farm animals by delivering to the farm animal an isolated

growth hormone secretagogue molecule that facilitates growth hormone secretion in the farm animal, classified in class 530, subclass 324.

The inventions are distinct, each from the other because of the following reasons: Group 1 is related to group 2 because each method could ultimately result in the delivery to tissues in an animal of GHRH. The methods are distinct because they require materially different substances with different functions. Groups 1 requires nucleic acids that encode variants of GHRH. These molecules must be delivered to appropriate cells that must express and secrete GHRH. As such the GHRH must be expressed in secretable form, i.e. with a signal sequence. Group 2 requires a mature peptide hormone that is delivered directly to cells in an animal, and is not secreted. Because the methods require physically and functionally distinct molecules, and have different modes of action, they are patentably distinct.

Because these inventions are distinct for the reasons given above, have acquired a separate status in the art as shown by their different classification and their recognized divergent subject matter, and because each invention requires a separate, non-coextensive search, restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Art Unit: 1635

remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(l).

Any inquiry concerning this communication or earlier communications from the examiner(s) should be directed to Richard Schnizer, whose telephone number is 571-272-0762. The examiner can normally be reached Monday through Friday between the hours of 6:00 AM and 3:30 PM. The examiner is off on alternate Fridays, but is sometimes in the office anyway.

If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Andrew Wang, can be reached at (571) 272-0811. The official central fax number is 571-273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other\_customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Richard Schnizer, Ph.D.